Application of Malopentaose in preparation of medicine for preventing or treating diabetes mellitus complicated by myocardial ischemia-reperfusion injury
By using Maltopentaose as a drug component, the problem of poor treatment of myocardial ischemia and reperfusion injury caused by diabetes was solved, and the cardiac function was significantly improved and the level of myocardial infarction markers was reduced, providing a new treatment strategy.
Patent Information
- Application Number
- CN202411278974.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-12
AI Technical Summary
The existing treatment strategies are not effective for myocardial ischemia and reperfusion injury due to diabetes, and are difficult to effectively prevent or treat, especially in reducing myocardial infarction and reversing impaired heart function.
Maltopentaose is used as a drug component to reduce oxidative stress, reduce cardiomyocyte apoptosis and myocardial infarction, and reduce myocardial infarction markers due to diabetes and myocardial ischemia and reperfusion injury. and reduce the area of myocardial infarction.
Maltopentaose significantly improved the heart function of mice with diabetes and myocardial ischemia and reperfusion injury, reversed the decrease in left ventricular ejaculation fraction and the shortening of the left ventricular short axis, reduced the level of myocardial infarction markers and myocardial infarction area, and provided new Therapeutic target.
Smart Images

Figure CN118987003A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of Maltopentaose in preparing medicine for preventing or treating diabetes-related myocardial ischemia-reperfusion injury, and belongs to the technical field of biomedicine. Background Art
[0002] Myocardial ischemia-reperfusion injury is the cellular metabolic dysfunction and tissue structural damage that accompanies the restoration of ischemic myocardial blood supply through reperfusion therapy. Diabetes destroys cell protection signals and increases the sensitivity of the myocardium to acute myocardial injury. Therefore, the injury after ischemia-reperfusion is more severe and more difficult to treat. The disease is characterized by myocardial infarction, accompanied by decreased ventricular systolic function, reduced left ventricular ejection fraction and left ventricular short-axis shortening. The disease has an acute onset and death can occur at any stage of the disease.
[0003] At present, some drugs are being studied to reduce myocardial ischemia-reperfusion injury, such as antioxidants, inflammation inhibitors, and apoptosis inhibitors. Myocardial protection, including coronary artery bypass grafting, myocardial hormone injection, and cryocooling, protects the myocardium by reducing cell damage caused by myocardial ischemia-reperfusion. Researchers are developing new monitoring methods, including myocardial enzyme marker detection, myocardial imaging, and biomarker analysis, to assess the extent of myocardial reperfusion injury and predict the prognosis of patients. Strategies to prevent myocardial reperfusion injury include improving preoperative management, reducing myocardial ischemia time, and increasing myocardial blood flow and oxygenation levels. In summary, researchers are exploring comprehensive treatment strategies that combine drug therapy, myocardial protection, and reperfusion injury monitoring to minimize the damage caused by myocardial ischemia-reperfusion. However, overall, current treatment measures cannot meet clinical needs for the prevention and treatment of myocardial ischemia-reperfusion injury complicated by diabetes. Finding new therapeutic targets has very important clinical scientific significance for the prevention or treatment of myocardial ischemia-reperfusion injury complicated by diabetes. Summary of the invention
[0004] In order to solve the above problems, the present invention provides the use of Maltopentaose in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury complicated by diabetes. Maltopentaose is the shortest oligosaccharide in maltodextrin, which is mostly used to study the saccharification and phosphorylation of α-lactalbumin and is currently commonly used to regulate intestinal flora.
[0005] The first object of the present invention is to provide the use of Maltopentaose in preparing a drug for preventing or treating myocardial ischemia-reperfusion injury complicated by diabetes.
[0006] In one embodiment, the CAS number of the Maltopentaose is 34620-76-3, and the structural formula is:
[0007]
[0008] In one embodiment, the characteristics of diabetes mellitus complicated with myocardial ischemia-reperfusion injury include, but are not limited to, increased oxidative stress, myocardial cell apoptosis, and impaired cardiac function.
[0009] In one embodiment, the drug is a drug that reduces oxidative stress, reduces impaired cardiac function, reduces cardiomyocyte apoptosis, reduces myocardial infarction, and reverses myocardial damage.
[0010] In one embodiment, the mitigation of impaired cardiac function includes but is not limited to reversing the reduction in left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) caused by diabetes-related myocardial ischemia-reperfusion injury.
[0011] In one embodiment, the mitigation of myocardial infarction and reversal of myocardial damage include but are not limited to lowering the levels of CK-MB, LDH, and c-Tnl.
[0012] In one embodiment, the drug contains the above-mentioned drug ingredients and pharmaceutically acceptable excipients.
[0013] In one embodiment, the auxiliary material includes any one of a carrier, a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an emulsifier, a solubilizer, a solubilizing agent, an osmotic pressure regulator, a surfactant, a coating material, a colorant, a pH regulator, an antioxidant, an antibacterial agent or a buffer, or a combination of at least two thereof.
[0014] In one embodiment, the carrier is one or more of a virus, a liposome, and a nanoparticle.
[0015] In one embodiment, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.
[0016] In one embodiment, the dosage form of the drug includes any one of drops, oral liquid, tablets, capsules, granules, films, gels, powders, emulsions, pills or solutions.
[0017] In one embodiment, the administration route of the drug includes oral administration, sublingual administration, rectal administration, skin mucosal administration, inhalation administration or injection administration.
[0018] The second object of the present invention is to provide a drug for preventing or treating diabetes-related myocardial ischemia-reperfusion injury, wherein the active ingredient of the drug includes Maltopentaose.
[0019] In one embodiment, the drug contains the above-mentioned drug ingredients and pharmaceutically acceptable excipients.
[0020] In one embodiment, the auxiliary material includes any one of a carrier, a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an emulsifier, a solubilizer, a solubilizing agent, an osmotic pressure regulator, a surfactant, a coating material, a colorant, a pH regulator, an antioxidant, an antibacterial agent or a buffer, or a combination of at least two thereof.
[0021] In one embodiment, the carrier is one or more of a virus, a liposome, and a nanoparticle.
[0022] In one embodiment, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.
[0023] In one embodiment, the dosage form of the drug includes any one of drops, oral liquid, tablets, capsules, granules, films, gels, powders, emulsions, pills or solutions.
[0024] In one embodiment, the administration route of the drug includes oral administration, sublingual administration, rectal administration, skin mucosal administration, inhalation administration or injection administration.
[0025] In one embodiment, the drug of the present invention has at least one or more of the following functions:
[0026] (1) Reverse the decrease in left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) caused by myocardial ischemia-reperfusion injury in diabetic patients;
[0027] (2) Reduce the levels of CK-MB, LDH, and c-Tnl;
[0028] (3) Reduce cardiomyocyte apoptosis and oxidative damage;
[0029] (4) Reduce oxidative stress and reduce the production of ROS;
[0030] (5) Reduce the area of myocardial infarction.
[0031] Beneficial effects:
[0032] The present invention finds that Maltopentaose can improve the cardiac function of diabetic mice complicated with myocardial ischemia-reperfusion injury, reverse the decrease of left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) caused by diabetic mice complicated with myocardial ischemia-reperfusion injury, reduce myocardial cell apoptosis, reduce the levels of myocardial infarction markers CK-MB, LDH and c-Tnl, and reduce the area of myocardial infarction, thereby preventing and treating diabetic mice complicated with myocardial ischemia-reperfusion injury, and provide a new target for preparing drugs for preventing and treating diabetic mice complicated with myocardial ischemia-reperfusion injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The effect of Maltopentaose on improving cardiac function in diabetic mice with myocardial ischemia-reperfusion injury. (A) Left ventricular ejection fraction (EF); (B) Left ventricular fractional shortening (FS); (C) Serum levels of myocardial infarction markers CK-MB, LDH and c-Tnl. *p<0.05vs.Sham,
[0034] Figure 2 The effect of Maltopentaose on improving the heart damage of diabetic mice complicated with myocardial ischemia-reperfusion injury. (A) HE staining of heart sections; (B) DHE staining of heart sections; (C) PI staining of heart sections.
[0035] Figure 3 The effect of Maltopentaose on improving the myocardial infarction level in diabetic mice with myocardial ischemia-reperfusion injury. The left picture is TTC staining; the right picture is the statistics of myocardial infarction area. *p<0.05vs.Sham, DETAILED DESCRIPTION
[0036] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation methods, structures, features and effects of the present invention are described in detail below in conjunction with the accompanying drawings and preferred embodiments. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0037] Maltopentaose was purchased from MCE Company (HY-N1495).
[0038] Example 1: Verification of the effect of Maltopentaose on diabetic myocardial ischemia-reperfusion injury
[0039] Male C57BL / 6 mice were purchased from Spef (Beijing) Biotechnology Co., Ltd. All mice were housed in specific pathogen-free micro-isolator cages and were free to eat and drink. The animals were kept in a room with controlled temperature and humidity and a 12-hour light / dark cycle. Male C57BL / 6 mice were divided into 3 groups, two of which were intraperitoneally injected with 0.2% streptozotocin at a dose of 50 mg / kg to induce diabetic mice for 5 consecutive days. Three days after the injection, the random blood glucose of the mice was measured, and mice with blood glucose concentration ≥16.7 mmol / L were considered to have successfully established the model. The normal control group was given an equal amount of citrate buffer (Sham group). The two groups of mice with successful diabetic model construction were injected with Maltopentaose (30 mg / kg) and an equal amount of normal saline, respectively. One day later, the blood supply to the myocardium was blocked by ligating the anterior descending branch of the coronary artery, causing myocardial ischemia for 30 minutes and reperfusion for 24 hours, respectively, DI / R+Maltopentaose group and DI / R group (diabetes complicated with myocardial ischemia-reperfusion model). To detect cardiac function, mice were euthanized, and blood samples and heart tissues were collected for biochemical analysis.
[0040] Transthoracic cardiac ultrasound was performed on mice using the Vevo 2100 high-resolution imaging system (Visualsonics, Toronto, ON, Canada) and a 30 MHz probe. Mice were fully anesthetized with isoflurane, placed on a heating pad, and adjusted to expose the chest to the ultrasound probe. Ultrasound gel was applied to the mouse chest, the ultrasound probe was placed on the chest area coated with ultrasound gel, and the Vevo 2100 system was started for image acquisition. The left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) of the mice were measured. Figure 1 AB showed that the EF and FS values of the normal control group (Sham group) were 74.65±7.30% and 41.68±5.23%; the EF and FS values of the diabetic mice complicated with myocardial ischemia-reperfusion model (DI / R group) were 52.10±6.49% and 26.61±3.56%, which were significantly lower than those of the control group; while the EF and FS values of the mice in the DI / R+Maltopentaose group were 64.81±4.43% and 35.65±2.03%, which were significantly higher than those of the DI / R group, that is, the EF and FS values of the mice given Maltopentaose after diabetic mice complicated with myocardial ischemia-reperfusion were significantly restored. The above results show that Maltopentaose can improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of mice and alleviate the damage of cardiac function.
[0041] The mouse blood samples were kept at room temperature for 2 h and centrifuged at 3000 rpm for 10 min to obtain the upper serum. Lactate dehydrogenase (LDH), creatine phosphokinase-isoenzyme MB (CK-MB) and troponin I (c-Tnl) kits were purchased from Nanjing Jiancheng Biotechnology Co., Ltd. and the tests were completed strictly according to the instructions of the corresponding ELISA test kits. Figure 1 C shows that the LDH level of the DI / R group increased by 2.4 times compared with the Sham group, while that of the DI / R+Maltopentaose group mice decreased by 50%. The CK-MB level of the DI / R group increased by 1 times compared with the Sham group, while that of the DI / R+Maltopentaose group mice decreased by 40%, close to the level of the control group. The c-Tnl level of the DI / R group increased by 2 times compared with the Sham group, while that of the DI / R+Maltopentaose group mice decreased by 40%. In summary, the present invention detected the levels of myocardial infarction markers CK-MB, LDH, and c-Tnl in mouse serum through ELISA and found that Maltopentaose can reduce the expression level of myocardial infarction markers.
[0042] like Figure 2 As shown, the hearts of the mice in the above three groups were taken for HE ( Figure 2 A) DHE( Figure 2 B) and PI staining ( Figure 2 C). In HE staining, it was found that the myocardium of mice in the DI / R group showed significant pathological damage, while the DI / R+Maltopentaose group could improve myocardial pathological damage. The DHE staining results showed that compared with the normal control group, the ROS level in the heart of mice with diabetes complicated by myocardial ischemia-reperfusion model was significantly increased, and the ROS level was reduced after administration of Maltopentaose. The statistical results of the relative fluorescence intensity of PI staining showed that the number of live cells in the heart of mice with diabetes complicated by myocardial ischemia-reperfusion model decreased, while the number of dead cells increased, while the number of live cells in mice treated with Maltopentaose increased, while the number of dead cells decreased. In summary, the present invention found that the oxidative stress of myocardial cells in mice with diabetes complicated by myocardial ischemia-reperfusion model increased, leading to cell apoptosis, and Maltopentaose could improve myocardial pathological damage in model mice and reduce myocardial cell apoptosis and oxidative damage.
[0043] The hearts of the three groups of mice were stained with TTC and counted to evaluate cardiac ischemic damage. Ischemic or necrotic tissues were not stained with TTC due to the loss of dehydrogenase activity and appeared pale. Figure 3 As shown, the present invention found that Maltopentaose significantly reduced the myocardial infarction area of diabetic mice complicated with myocardial ischemia-reperfusion injury by about 40%.
[0044] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.
Claims
1. The use of Maltopentaose in the preparation of drugs for preventing or treating myocardial ischemia-reperfusion injury complicated by diabetes.
2. The use according to claim 1, It is characterized in that The CAS number of the Maltopentaose is 34620-76-3, and the structural formula is:
3. The use according to claim 1, It is characterized in that The characteristics of diabetes-complicated myocardial ischemia-reperfusion injury include, but are not limited to, increased oxidative stress, myocardial cell apoptosis, and impaired cardiac function.
4. The use according to claim 1, It is characterized in that The medicine is a medicine for reducing oxidative stress, reducing impaired cardiac function, reducing myocardial cell apoptosis, reducing myocardial infarction, and reversing myocardial damage.
5. The use according to claim 1, It is characterized in that The dosage form of the drug includes any one of drops, oral liquid, tablets, capsules, granules, films, gels, powders, emulsions, pills or solutions.
6. The use according to claim 1, It is characterized in that The medicine contains the above-mentioned drug components and pharmaceutically acceptable excipients.
7. The use according to claim 6, It is characterized in that The auxiliary materials include any one of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.
8. The use according to claim 1, It is characterized in that The administration routes of the drug include oral administration, sublingual administration, rectal administration, skin and mucosal administration, inhalation administration or injection administration.
9. A drug for preventing or treating myocardial ischemia-reperfusion injury complicated by diabetes mellitus. It is characterized in that The active ingredient of the drug includes Maltopentaose.
10. The drug according to claim 9, It is characterized in that The CAS number of the Maltopentaose is 34620-76-3, and the structural formula is:
Citation Information
Patent Citations
Traditional Chinese medicine composition for preventing or treating metabolic cardiomyopathy
CN114306490A
New application of dendrobium oligosaccharide
CN114796245A
Optimal formula of small molecule active peptide for relieving cardiac ischemia condition, improving myocardial ultrastructure and repairing damaged myocardial cells
CN116268426A
Sulfated maltooligosaccharides with heparin-like properties
US5739115A
